Investor Presentaiton
Radiopharmaceutical sector transactions
The radiopharmaceutical market is niche and highly acquisitive
Advanced
Accelerator
Applications
ENDOCYTE
ALGETA
Completed Phase 3 with LutatheraⓇ in Sep
2015, market entry was early 2018
Acquired by Novartis for USD3.9 billion in
cash in 2018
Licensed PSMA-617 after Phase 2a for ~USD14 million
upfront with additional milestones and royalties. Their
market cap. over USD1 billion after FDA meeting and
financing to start a Phase 3 trial
October 2018, Novartis announced the acquisition of
Endocyte for USD2.1 billion
Bayer acquired Algeta ASA for
USD2.9 billion in 2014 to
develop its metastatic
prostate-cancer product
Xofigo®
Curium™
LIFE FORWARD
BLUE EARTH
DIAGNOSTICS
A Bracco Company
Progenics
Pharmaceuticals
IBA Molecular acquired
Mallinckrodt's nuclear imaging
business for USD690 million in 2017
Syncona completed sale of Blue
Earth Diagnostics to Bracco Imaging
for $476.3m (£390.2m) in 2019
Acquired by Lantheus Holdings for
approximately USD430 million in 2020
CLARITY
2014 ME
4View entire presentation